Your browser is no longer supported. Please, upgrade your browser.
Settings
CGEN Compugen Ltd. daily Stock Chart
CGEN [NASD]
Compugen Ltd.
Index- P/E- EPS (ttm)-0.55 Insider Own12.00% Shs Outstand60.39M Perf Week-3.47%
Market Cap201.70M Forward P/E- EPS next Y-0.49 Insider Trans0.00% Shs Float59.74M Perf Month-6.96%
Income-31.10M PEG- EPS next Q-0.15 Inst Own24.30% Short Float5.27% Perf Quarter-2.62%
Sales7.80M P/S25.86 EPS this Y43.50% Inst Trans1.46% Short Ratio25.63 Perf Half Y5.36%
Book/sh0.55 P/B6.07 EPS next Y10.90% ROA-60.40% Target Price9.00 Perf Year-4.57%
Cash/sh- P/C- EPS next 5Y- ROE-83.40% 52W Range2.00 - 4.31 Perf YTD53.92%
Dividend- P/FCF- EPS past 5Y-2.40% ROI-62.40% 52W High-22.51% Beta2.64
Dividend %- Quick Ratio5.10 Sales past 5Y38.10% Gross Margin91.20% 52W Low67.00% ATR0.17
Employees89 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)40.67 Volatility3.23% 5.37%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.28 Prev Close3.34
ShortableYes LT Debt/Eq0.00 EarningsAug 19 BMO Payout- Avg Volume122.82K Price3.34
Recom1.00 SMA20-8.28% SMA50-3.54% SMA200-1.49% Volume0 Change0.00%
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Jul-22-19 07:00AM  Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET PR Newswire
Jul-16-19 07:00AM  Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody PR Newswire
Jul-02-19 07:00AM  Compugen Appoints Eran Perry to Its Board of Directors PR Newswire
Jun-27-19 03:07PM  How Many Compugen Ltd. (NASDAQ:CGEN) Shares Do Institutions Own? Simply Wall St.
03:05PM  Do Institutions Own Shares In Compugen Ltd. (NASDAQ:CGEN)? Simply Wall St.
Jun-26-19 09:00AM  Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jun-12-19 09:14AM  The Compugen (NASDAQ:CGEN) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold Simply Wall St.
Jun-03-19 07:00AM  Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting PR Newswire
May-23-19 09:00AM  Compugen (CGEN) Upgraded to Buy: Here's What You Should Know Zacks
May-22-19 07:00AM  Compugen to Present at the Jefferies 2019 Healthcare Conference PR Newswire
May-20-19 06:08PM  Stocks Close Lower on Monday GuruFocus.com
04:00PM  Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript Motley Fool
10:13AM  Compugen: 1Q Earnings Snapshot Associated Press
07:05AM  Compugen Reports First Quarter 2019 Results PR Newswire
07:00AM  Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors PR Newswire
May-06-19 07:00AM  Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET PR Newswire
Apr-18-19 09:00AM  What Makes Compugen (CGEN) a New Strong Buy Stock Zacks
Apr-03-19 07:00AM  Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting PR Newswire
Mar-26-19 08:40AM  Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules PR Newswire +7.26%
07:00AM  Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management PR Newswire
Mar-12-19 07:46AM  Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate PR Newswire
Mar-08-19 10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
Mar-07-19 09:09AM  Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
09:06AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
Mar-05-19 07:00AM  Compugen to Present at the Cowen and Company 39th Annual Health Care Conference PR Newswire
Mar-01-19 07:00AM  Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire
Feb-26-19 02:00AM  Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations PR Newswire -17.02%
Feb-14-19 07:00AM  Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET PR Newswire
Jan-22-19 07:00AM  Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy PR Newswire +12.62%
Jan-16-19 07:07AM  How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own? Simply Wall St.
Jan-14-19 07:00AM  Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire
Nov-23-18 08:20AM  New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-13-18 07:00AM  Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy PR Newswire
Nov-07-18 08:20AM  Compugen (CGEN) Reports Q3 Loss Zacks +14.29%
07:20AM  Compugen: 3Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports Third Quarter 2018 Results PR Newswire
Nov-05-18 05:35AM  Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-24-18 07:15AM  Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET PR Newswire -7.49%
Oct-12-18 03:09PM  Don't Fixate On Market Woes, Just Make Your Trades Benzinga
10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
09:30AM  Bristol-Myers Inks Deal and Invests $12 Million in Compugen Zacks
Oct-11-18 07:32AM  Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake MarketWatch +7.69%
07:00AM  Bristol-Myers to invest in Compugen, collaborate in clinical trials Reuters
06:59AM  Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors PR Newswire
Sep-20-18 07:00AM  Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial PR Newswire
Sep-14-18 01:27PM  Should You Have Compugen Ltds (NASDAQ:CGEN) In Your Portfolio? Simply Wall St.
Sep-07-18 07:00AM  Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial PR Newswire
Sep-05-18 07:00AM  Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors PR Newswire
Aug-01-18 07:28AM  Compugen: 2Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports Second Quarter 2018 Results PR Newswire
06:30AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE
Jul-18-18 07:00AM  Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET PR Newswire
Jul-02-18 09:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:05AM  Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254 PR Newswire
07:00AM  Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody PR Newswire
Jun-27-18 12:38PM  When Should You Buy Compugen Ltd (NASDAQ:CGEN)? Simply Wall St. -8.33%
Jun-15-18 07:00AM  Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants PR Newswire
Jun-11-18 07:00AM  Compugen Announces the Appointment of New Board Members PR Newswire
May-16-18 08:53AM  Market Has Not Yet Noticed Potential in Compugen; Have You? Zacks
May-09-18 07:58AM  Compugen: 1Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports First Quarter 2018 Results PR Newswire
May-02-18 07:14PM  Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You? Simply Wall St.
Apr-30-18 07:00AM  Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET PR Newswire
Apr-27-18 07:24AM  Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody PR Newswire -7.79%
Apr-19-18 07:40AM  Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugens BAY 1905254 Efficacy in Cancer Immunotherapy ACCESSWIRE
Apr-17-18 07:00AM  Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy PR Newswire
Apr-03-18 01:00AM  [$$] AstraZeneca receives regulatory boost for oncology drugs Financial Times
Apr-02-18 10:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:25AM  Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products PR Newswire
07:01AM  Compugen, AstraZeneca unit in cancer drug development deal Reuters
07:00AM  Compugen, AstraZeneca unit in cancer drug development deal Reuters
Mar-28-18 12:38PM  At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy? Simply Wall St.
Mar-26-18 07:00AM  Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer PR Newswire
Mar-20-18 10:06AM  Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You? Simply Wall St.
Mar-08-18 07:00AM  Compugen to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Feb-21-18 07:50AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE +6.56%
07:31AM  Compugen reports 4Q loss Associated Press
07:07AM  Compugen Reports Fourth Quarter and Full Year 2017 Results PR Newswire
Feb-08-18 07:40AM  Wired News Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases ACCESSWIRE
07:00AM  Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET PR Newswire
Feb-06-18 07:06AM  Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology PR Newswire
Jan-18-18 07:00AM  Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors PR Newswire +18.18%
Jan-02-18 07:00AM  Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences PR Newswire +8.00%
Dec-18-17 06:05PM  What You Must Know About Compugen Ltds (NASDAQ:CGEN) Financial Health Simply Wall St.
Dec-01-17 12:50PM  How Compugen Ltds (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too? Simply Wall St.
Nov-15-17 12:37PM  Is It Too Late To Buy Compugen Ltd (CGEN)? Simply Wall St. +7.84%
Nov-07-17 08:20AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE
07:17AM  Compugen reports 3Q loss Associated Press
07:10AM  Compugen Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
07:00AM  Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody PR Newswire
Nov-02-17 07:00AM  Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets PR Newswire
Oct-26-17 07:00AM  Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month PR Newswire
Oct-25-17 07:00AM  Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET PR Newswire -5.80%
Oct-11-17 07:50AM  Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032 ACCESSWIRE
Oct-10-17 08:30AM  Company News For Oct 10, 2017 Zacks
Oct-09-17 09:21AM  Flexion Shares Continue Rise After FDA Approval -- Biotech Movers TheStreet.com +7.04%
07:00AM  A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy PR Newswire
Oct-02-17 09:47AM  Compugen Ltd (CGEN): How Does It Impact Your Portfolio? Simply Wall St. -6.58%
Aug-07-17 07:00AM  Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month PR Newswire
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel.